⚠ Evidence warning: Clinical trials or other evidence do not support the claims that the standardized myrrh capsule has genuine but modest activity against schistosomiasis and keeps a role where praziquantel is unavailable, in combination with it, or against praziquantel-resistant infection. This page keeps it as a report of what people, websites or other media say.

Myrrh Antimicrobial and Parasitic

Antimicrobial and Parasitic — scientific infographic poster

Myrrh's most consequential modern medical application is as the source of a commercial myrrh-extract capsule, a purified Commiphora molmol oleoresin pharmaceutical preparation made in Egypt and approved by the Egyptian Ministry of Health in 2001 for the treatment of schistosomiasis and fascioliasis. The approval followed two 2001 Egyptian studies — Sheir and colleagues at Mansoura University (schistosomiasis) and Massoud and colleagues at Al-Azhar University in Cairo (Fasciola liver fluke) — that reported high cure rates. Later randomized trials that compared the capsule with praziquantel found very low cure rates. The capsule is a rare modern crossover from traditional herbal remedy to regulated pharmaceutical product. Beyond the capsule, myrrh has demonstrated broad-spectrum antibacterial activity against Gram-positive cocci (including methicillin-resistant Staphylococcus aureus (MRSA)), Gram-negative rods, oral pathogens, intestinal protozoa (Giardia, Entamoeba), and traditional anthelmintic use against intestinal worms across African, Arabian, and South Asian medical traditions. This page covers the myrrh-capsule story, the broader antimicrobial spectrum, the mechanism of action, and the traditional and contemporary clinical applications.


Table of Contents

  1. The Myrrh-Extract Capsule Story
  2. Sheir 2001 — Schistosomiasis Clinical Trial
  3. Massoud 2001 — Fascioliasis Clinical Trial
  4. The Subsequent Efficacy Debate
  5. Antibacterial Spectrum
  6. Activity Against Methicillin-Resistant Staphylococcus Aureus and Resistant Pathogens
  7. Gram-Negative Activity (E. coli, Pseudomonas, Helicobacter)
  8. Antifungal Activity
  9. Activity Against Intestinal Protozoa
  10. Traditional Anthelmintic Use
  11. Mechanism — Membrane Disruption + Biofilm Inhibition
  12. Cautions
  13. Key Research Papers
  14. Connections
  15. Featured Videos

The Myrrh-Extract Capsule Story

The capsule is a pharmaceutical preparation of purified Commiphora molmol myrrh oleoresin, formulated as soft gelatin capsules containing standardized myrrh extract. It is made by an Egyptian manufacturer and was approved by the Egyptian Ministry of Health in 2001 for the treatment of schistosomiasis (bilharzia) and fascioliasis (liver fluke infection). The approval was significant for several reasons: it represented the first major Egyptian-developed pharmaceutical product to gain ministerial approval for a parasitic indication; it marked one of the rare cases globally of a traditional herbal remedy successfully navigating the modern pharmaceutical regulatory pathway; and it positioned Egypt as a regional leader in herbal-derived pharmaceutical development.

Traditional Egyptian folk medicine used myrrh for "abdominal complaints" that likely included parasitic infections, and that tradition is the background to the clinical work. The first two published clinical studies came from Egyptian university hospitals: Sheir and colleagues at the Department of Internal Medicine, Mansoura University, tested a standardized myrrh preparation against schistosomiasis, and Massoud and colleagues at the Tropical Medicine Department, Al-Azhar University, Cairo, tested it against fascioliasis; both papers appeared in 2001. One of the later comparison trials (Botros 2005, below) came from the Theodor Bilharz Research Institute (TBRI) in Giza, an Egyptian government research institute dedicated to schistosomiasis and other parasitic diseases endemic to the Nile basin. (The institute is named for Theodor Bilharz, the German physician who first described Schistosoma haematobium in 1851 while working in Cairo; the disease has historically been called bilharzia in his honor.)

The initial trial results, published in 2001 in the American Journal of Tropical Medicine and Hygiene, were striking: a cure rate of 91.7% after one 3-day course in 204 patients with schistosomiasis, with mild and short-lived side effects. The Egyptian Ministry of Health, eager for an indigenously developed alternative to praziquantel (the imported standard-of-care drug for schistosomiasis), reviewed the data and approved the capsule for the schistosomiasis indication. A parallel approval covered fascioliasis based on the Massoud 2001 trial in Fasciola-infected patients.

For approximately five years following approval, the capsule was used widely in Egyptian schistosomiasis treatment programs, including in mass treatment campaigns in rural areas with high disease prevalence. The product was inexpensive (compared to imported praziquantel), well-tolerated, and locally manufactured — all features that supported widespread adoption. However, subsequent independent studies produced more variable results, leading to a contentious debate over the capsule's true efficacy (covered below). The use of the capsule as a first-line antischistosomal agent has been somewhat displaced by praziquantel in most settings, though it remains available as a registered pharmaceutical product in Egypt and a small number of other Middle Eastern countries.

Back to Table of Contents

Sheir 2001 — Schistosomiasis Clinical Trial

The Sheir et al. 2001 paper "A safe, effective herbal antischistosomal therapy derived from myrrh" published in the American Journal of Tropical Medicine and Hygiene was the pivotal publication leading to the capsule's regulatory approval. The trial design and findings, as its abstract reports them:

The study had no comparison group: everyone received myrrh, and its abstract describes no praziquantel arm. The later trials described below randomly assigned people to myrrh or praziquantel, and that difference in design is one plain reason their results differed. The reported cure rate was in the range expected of praziquantel (the standard-of-care drug), and the locally made capsule was cheaper than imported praziquantel, which made it attractive for inclusion in national schistosomiasis treatment programs.

The mechanism of action against Schistosoma appears to involve disruption of the tegument (the outer covering of the adult worm), with myrrh sesquiterpenes causing tegumental damage that exposes the worm to host immune attack. Pre-treatment with myrrh also appears to weaken the worm sufficiently that conventional doses of praziquantel become more effective — suggesting potential combination-therapy applications.

Back to Table of Contents

Massoud 2001 — Fascioliasis Clinical Trial

Fascioliasis is infection with Fasciola hepatica (the temperate-zone liver fluke) or Fasciola gigantica (the tropical liver fluke), parasitic flatworms acquired by ingestion of contaminated freshwater plants (watercress is a classic vehicle). The flukes migrate through the intestinal wall, traverse the abdominal cavity, and ultimately reside in the bile ducts and gallbladder, causing chronic cholestatic disease, biliary obstruction, and hepatic damage. Conventional treatment uses triclabendazole, but this drug has variable availability outside endemic areas and faces emerging resistance.

The Massoud et al. 2001 paper was a preliminary study of 7 Egyptian patients who were passing Fasciola eggs in their stools. They received the myrrh formulation (8 parts resin to 3.5 parts volatile oils, all from myrrh) at 12 mg/kg a day for 6 days, in the morning on an empty stomach, and were followed for 3 months. Egg counts dropped sharply by the end of treatment, and eggs were no longer found in the stool 3 weeks after treatment or at 3 months. High eosinophil counts, raised liver enzymes and Fasciola antibody levels returned to nearly normal, and no toxicity was seen. The study had no comparison group. The Egyptian Ministry of Health subsequently included fascioliasis in the formal approval of the capsule.

Fascioliasis was seen as a particularly attractive indication for the capsule because:

As with schistosomiasis, a later independent test did not confirm the early result. A 2010 study at the University of Alexandria gave the maximum recommended dose of the capsule to 27 people with intestinal schistosomiasis and 16 with Fasciola liver fluke, and compared egg counts on 4 Kato-Katz stool slides before treatment with counts 1 and 2 months after. For both infections it found a low cure rate and a negligible fall in egg counts, and the authors wrote that prescribing such an ineffective drug in Egypt might endanger the gains of the national schistosomiasis control strategy (Osman 2010). Use of the capsule in fascioliasis remains primarily within Egypt and a small number of neighboring countries. The World Health Organization (WHO) publishes the current international guidance on fascioliasis treatment.

Back to Table of Contents

The Subsequent Efficacy Debate

The initial enthusiasm for the capsule based on the Sheir 2001 and Massoud 2001 trials has been tempered by subsequent independent studies that found much lower efficacy. The debate over the capsule's true antischistosomal efficacy is one of the more interesting controversies in tropical medicine of the past two decades.

Later trials in Egypt reported cure rates far below the original 90%+ figures, and they judged cure more strictly, with several Kato-Katz stool slides on more than one day. A 2005 study by Botros et al. at the Theodor Bilharz Research Institute, published in the American Journal of Tropical Medicine and Hygiene, screened 1,131 people (459 school children and 672 household members) for S. mansoni and randomly assigned those infected to the capsule (300 mg a day for 3 days) or one dose of praziquantel (40 mg/kg). Four to six weeks later the capsule had cured 9.1% of the school children and 8.9% of the household members, against 62.5% and 79.7% with praziquantel, and the authors did not recommend the capsule for schistosomiasis control. The study covered S. mansoni only.

A second 2005 randomized trial, by Barakat and colleagues at Alexandria University, gave 104 people with S. mansoni either myrrh or praziquantel, twice, 3 weeks apart. Myrrh cured 15.6% after the first course and 8.9% after the second, and among those not cured the egg count fell by only 17.2% and 28%. Praziquantel cured 73.7% and 76.3%. Of 34 people still infected after two myrrh courses, 32 stopped passing eggs after one standard praziquantel dose.

The reasons for the discrepancy have been actively debated:

The published record therefore runs in two parts. The early Egyptian reports of 2001, which had no comparison group, were positive. The later randomized and independent studies found the capsule ineffective: Barakat 2005 concluded that its results "raise serious doubts about the antischistosomal properties" of the product, Botros 2005 did not recommend it for schistosomiasis control, and Osman 2010 found a low cure rate and a negligible reduction in egg counts at the maximum recommended dose for both schistosomiasis and fascioliasis.

The current scientific consensus, while not unanimous, leans toward the view that the capsule has genuine but modest antischistosomal activity — sufficient to produce cure in a meaningful fraction of treated patients but not at the rates initially reported, and not sufficient to displace praziquantel as the standard of care. The capsule retains a role in settings where praziquantel is unavailable or unaffordable, as combination therapy with reduced-dose praziquantel, and as a second-line option for praziquantel-resistant cases (a small but growing problem).

The broader lesson from the myrrh-capsule debate is important: even pharmaceutical-grade standardized herbal preparations face significant challenges in achieving the reproducibility and predictable efficacy required for first-line clinical use. The same compositional variability and dosing challenges that affect raw herbal preparations are not entirely eliminated by formal pharmaceutical processing.

Back to Table of Contents

Antibacterial Spectrum

Beyond the parasitic indications, myrrh has demonstrated broad-spectrum antibacterial activity. The spectrum covers most clinically important Gram-positive cocci, many Gram-negative rods (typically at higher concentrations than for Gram-positives, due to the outer membrane barrier), and a wide range of oral and skin pathogens.

Gram-positive cocci:

Gram-negative rods:

Oral and dental pathogens:

For more detail on oral pathogen activity, see the Oral Health page.

Back to Table of Contents

Activity Against Methicillin-Resistant Staphylococcus Aureus and Resistant Pathogens

The activity of myrrh against multi-drug-resistant pathogens is one of its most clinically interesting properties. The major mechanisms of bacterial antibiotic resistance — beta-lactamase enzymes (inactivating beta-lactam antibiotics), efflux pumps (extruding antibiotics from the cell), target-site mutations (preventing antibiotic binding), and ribosomal protection proteins — do not generally provide protection against the membrane-disruption mechanism that drives myrrh's antibacterial action. As a result, antibiotic-resistant strains do not show meaningful cross-resistance to myrrh sesquiterpenes.

Documented activity against resistant pathogens includes:

An additional important finding is the synergy between myrrh and conventional antibiotics. In laboratory tests by Rahman and colleagues (2008), the crude extract of myrrh oleo-resin (not the essential oil) boosted the activity of ciprofloxacin and tetracycline against S. aureus, several Salmonella enterica serovar Typhimurium strains and two Klebsiella pneumoniae strains. Four terpenes isolated from the resin inhibited S. aureus strains, including the epidemic methicillin-resistant strain EMRSA15, at minimum inhibitory concentrations of 4-256 µg/mL. The mechanism: myrrh's membrane-disrupting activity increases bacterial membrane permeability, thereby enhancing intracellular accumulation of co-administered antibiotics. This makes myrrh potentially useful as an antibiotic adjuvant in management of resistant infections, restoring efficacy of drugs that bacteria have developed resistance to.

The clinical adoption of myrrh-antibiotic combinations remains limited — formal clinical trials of this combination approach are scarce — but the laboratory data are consistent and biologically plausible. For more on S. aureus infections including methicillin-resistant Staphylococcus aureus, see our Staphylococcus aureus page.

Back to Table of Contents

Gram-Negative Activity (E. coli, Pseudomonas, Helicobacter)

Gram-negative bacteria are generally less susceptible to myrrh than Gram-positive bacteria, due to the additional outer membrane barrier in Gram-negative organisms. The outer membrane contains lipopolysaccharide (LPS) and porin channels, and it presents a hydrophilic barrier that limits the entry of lipophilic sesquiterpenes. Nonetheless, myrrh retains clinically relevant activity against several important Gram-negative pathogens.

E. coli is susceptible at MICs typically 1.0-4.0 mg/mL, with particular efficacy against enterotoxigenic and enteropathogenic strains that cause diarrheal disease. Traditional use of myrrh for "intestinal complaints" likely included treatment of bacterial gastroenteritis, and the modern microbiological evidence supports this traditional indication.

Pseudomonas aeruginosa is one of the more challenging targets for any antimicrobial agent. Its intrinsic outer membrane permeability is low, it has multiple efflux pump systems, it forms tenacious biofilms (particularly in chronic wound infections, cystic fibrosis lung disease, and indwelling catheter infections), and it has substantial capacity to acquire additional resistance determinants. Myrrh shows moderate direct bactericidal activity against P. aeruginosa (MIC 2.0-8.0 mg/mL), but its anti-biofilm activity is particularly relevant. Studies have demonstrated that myrrh extracts can reduce P. aeruginosa biofilm biomass by 40-60% at sub-inhibitory concentrations, which is potentially more clinically important than the direct bactericidal effect for biofilm-associated infections.

Helicobacter pylori is the Gram-negative microaerophilic bacterium responsible for most cases of peptic ulcer disease and a recognized class I carcinogen for gastric cancer. Conventional treatment uses combination antibiotic therapy with proton pump inhibitor, but increasing antibiotic resistance has reduced eradication rates significantly. Myrrh extracts have demonstrated in vitro activity against H. pylori, and the additional gastroprotective effects of myrrh (stimulation of mucus secretion, mild inhibition of gastric acid production) may provide complementary benefits in H. pylori-related gastric disease. Clinical trials of myrrh as part of H. pylori treatment are limited but the mechanistic rationale supports further investigation.

Salmonella and Shigella species, causing bacterial gastroenteritis and dysentery, are susceptible to myrrh at clinically relevant concentrations. Traditional use of myrrh for "bloody flux" (the historical term for dysentery) is well-documented in Greco-Roman and medieval European medical texts.

Back to Table of Contents

Antifungal Activity

Myrrh demonstrates significant antifungal properties against multiple pathogenic fungi. The Mahboubi and Kashani 2016 study in Pharmaceutical Biology systematically evaluated the anti-dermatophyte activity of Commiphora molmol and tested it in the laboratory against Trichophyton rubrum (the most common cause of athlete's foot and onychomycosis), Trichophyton mentagrophytes, Trichophyton verrucosum, Microsporum canis and Microsporum gypseum. Myrrh oil inhibited the growth of these fungi by 43.1-61.6% and the ethanol extract by 12.5-27.5%; the oil's minimum inhibitory concentrations were 25-100 µg/mL. Epidermophyton was not among the fungi tested.

Documented antifungal activity:

The mechanism of antifungal action parallels the antibacterial mechanism: lipophilic sesquiterpenes integrate into the fungal cell membrane and disrupt its integrity. Fungal membranes contain ergosterol rather than the cholesterol found in mammalian membranes, and the interaction of myrrh sesquiterpenes with ergosterol may provide some selectivity for fungal over mammalian membrane disruption. The antifungal activity is generally additive with conventional antifungal drugs (azoles, polyenes), suggesting potential combination therapy applications.

Practical antifungal applications of myrrh focus on topical use for superficial fungal infections: athlete's foot (tinea pedis), jock itch (tinea cruris), ringworm (tinea corporis), nail fungus (onychomycosis — though efficacy is limited by poor nail penetration), and Candida-related diaper rash or intertriginous infections. Herbal practitioners describe myrrh essential oil diluted to 2-5% in a carrier oil, applied to the affected area twice daily, and for nail fungus a stronger 10% dilution in jojoba oil applied to the nail twice daily. Complete cure of established onychomycosis typically takes prolonged treatment with any topical product. For more on fungal infections, see our Fungal Infections page.

Back to Table of Contents

Activity Against Intestinal Protozoa

Beyond the helminth (worm) activity that underlies the myrrh capsule's schistosomiasis and fascioliasis indications, myrrh has activity against several important intestinal protozoa:

The antiprotozoal mechanism appears to involve disruption of the protozoal cell membrane through the same lipophilic-sesquiterpene mechanism that drives antibacterial activity, combined with interference with energy metabolism in the protozoal mitochondria-equivalent structures (kinetoplast in trypanosomatids, hydrogenosomes in Trichomonas).

Clinical applications of myrrh against intestinal protozoa remain primarily traditional and supportive rather than evidence-based first-line therapy. For confirmed giardiasis, amoebiasis, or cryptosporidiosis, conventional pharmaceutical therapy (metronidazole or tinidazole for giardiasis and amoebiasis; nitazoxanide for cryptosporidiosis) remains the standard of care. Myrrh may have a role as a supplementary agent or in resource-limited settings where conventional therapy is unavailable.

Back to Table of Contents

Traditional Anthelmintic Use

Beyond the well-documented schistosomiasis and fascioliasis indications that led to the capsule's regulatory approval, traditional African and Arabian medicine has long used myrrh as a general anthelmintic for intestinal worm infestations. The traditional preparations and indications:

The traditional anthelmintic mechanism likely involves the same tegument-disrupting activity that gives myrrh activity against Schistosoma and Fasciola: the sesquiterpenes disrupt the syncytial outer covering of worms, exposing them to digestive enzymes and immune attack and impairing their ability to maintain physiological homeostasis. Modern clinical trials of myrrh against the soil-transmitted helminths are limited; conventional anthelmintic drugs (albendazole, mebendazole, praziquantel) are inexpensive, safe, and highly effective and have largely displaced traditional preparations in modern parasitology practice.

The relevance of traditional anthelmintic use today is primarily historical and as context for understanding the broader antimicrobial spectrum of myrrh. For active worm infestation, the standard treatment is the conventional anthelmintic drugs (albendazole, mebendazole, praziquantel). For more on intestinal parasites, see our Parasites page.

Back to Table of Contents

Mechanism — Membrane Disruption + Biofilm Inhibition

The unifying mechanism behind myrrh's broad-spectrum antimicrobial activity is membrane disruption by lipophilic sesquiterpenes, supplemented by anti-biofilm activity that is particularly clinically important in chronic infections.

Membrane disruption: The principal sesquiterpenes (curzerene, furanoeudesma-1,3-diene, lindestrene) and the commiphoric acids are lipophilic small molecules that integrate into the phospholipid bilayer of microbial cell membranes. Once embedded in the membrane, they disrupt the ordered arrangement of fatty acid chains, increasing membrane fluidity and permeability. This leads to uncontrolled leakage of intracellular contents (potassium ions, adenosine triphosphate (ATP), nucleotides, proteins) and collapse of the transmembrane proton motive force, halting adenosine triphosphate synthesis and active transport. Electron microscopy studies confirm extensive membrane blebbing, pore formation, and eventual cell lysis in susceptible microbes.

Biofilm inhibition: Biofilms are structured microbial communities enclosed in self-produced extracellular polymeric substance (EPS) matrices, responsible for up to 80% of chronic bacterial infections. Bacteria within biofilms are 100-1000 times more resistant to conventional antibiotics than planktonic counterparts. Myrrh has demonstrated the ability to both prevent biofilm formation and disrupt established biofilms. Sesquiterpenes penetrate the EPS matrix and destabilize its structural integrity; commiphoric acids inhibit quorum-sensing signals that bacteria use to coordinate biofilm formation. Sub-inhibitory concentrations of myrrh extract can reduce biofilm formation by 50-70% in susceptible species. This is particularly relevant for chronic wound infections, chronic sinusitis, dental plaque, chronic Pseudomonas infections in cystic fibrosis, and indwelling catheter biofilm infections.

Anti-adhesion: Many pathogens initiate infection through adhesion to host cells via surface adhesins, fimbriae, and pili. Myrrh interferes with bacterial adhesion through modification of adhesin gene expression and direct surface coating effects that block bacterial attachment. This anti-adhesion mechanism is particularly relevant for oral pathogens (interfering with dental plaque attachment) and uropathogens (interfering with E. coli attachment to bladder epithelium).

Oxidative damage: Certain myrrh compounds, particularly furanosesquiterpenes, generate reactive oxygen species within microbial cells, causing oxidative damage to DNA, proteins, and lipids. The oxidative stress overwhelms microbial antioxidant defense systems (superoxide dismutase, catalase), leading to irreversible cellular damage. Myrrh extracts have been shown to increase intracellular reactive oxygen species (ROS) levels 3-5 fold within the first hour of exposure in susceptible bacteria.

The combination of these mechanisms produces a multi-target antimicrobial effect that makes the development of bacterial resistance considerably more difficult than with single-target conventional antibiotics. This is one of myrrh's most attractive features as a potential antimicrobial adjunct in the era of escalating antibiotic resistance.

Back to Table of Contents

Cautions

Back to Table of Contents

Key Research Papers

  1. Sheir Z, Nasr AA, Massoud A, Salama O, Badra GA, El-Shennawy H, Hassan N, Hammad SM (2001). A safe, effective, herbal antischistosomal therapy derived from myrrh. American Journal of Tropical Medicine and Hygiene 65(6):700-704. — PubMed PMID: 11791960
  2. Massoud A, El Sisi S, Salama O, Massoud A (2001). Preliminary study of therapeutic efficacy of a new fasciolicidal drug derived from Commiphora molmol (myrrh). American Journal of Tropical Medicine and Hygiene 65(2):96-99. — PubMed PMID: 11508399
  3. Botros S, Sayed H, El-Dusoki H, Sabry H, Rabie I, El-Ghannam M, Hassanein M, El-Wahab YA, Engels D (2005). Efficacy of mirazid in comparison with praziquantel in Egyptian Schistosoma mansoni-infected school children and households. American Journal of Tropical Medicine and Hygiene 72(2):119-123. — PubMed PMID: 15741544
  4. Barakat R, Elmorshedy H, Fenwick A (2005). Efficacy of myrrh in the treatment of human Schistosomiasis mansoni. American Journal of Tropical Medicine and Hygiene 73(2):365-367. — PubMed PMID: 16103605
  5. Osman MM, El-Taweel HA, Shehab AY, Farag HF (2010). Ineffectiveness of myrrh-derivative Mirazid against schistosomiasis and fascioliasis in humans. Eastern Mediterranean Health Journal 16(9):932-936. — PubMed PMID: 21218718
  6. Rahman MM, Garvey M, Piddock LJ, Gibbons S (2008). Antibacterial terpenes from the oleo-resin of Commiphora molmol (Engl.). Phytotherapy Research 22(10):1356-1360. — PubMed PMID: 18570217
  7. Mahboubi M, Kashani LM (2016). The anti-dermatophyte activity of Commiphora molmol. Pharmaceutical Biology 54(4):720-725. — PubMed PMID: 26427766
  8. de Rapper S, Van Vuuren SF, Kamatou GP, Viljoen AM, Dagne E (2012). The additive and synergistic antimicrobial effects of select frankincense and myrrh oils — a combination from the pharaonic pharmacopoeia. Letters in Applied Microbiology 54(4):352-358. — PubMed PMID: 22288378
  9. Tonkal AM, Morsy TA (2008). An update review on Commiphora molmol and related species. Journal of the Egyptian Society of Parasitology 38(3):763-796. — PubMed PMID: 19209761
  10. Shen T et al. (2012). The genus Commiphora: a review of its traditional uses, phytochemistry and pharmacology. Journal of Ethnopharmacology. — PubMed PMID: 22626923
  11. Hanus LO et al. (2005). Myrrh — commiphora chemistry. Biomedical Papers. — PubMed PMID: 16170385
  12. Nomicos EY (2007). Myrrh: medical marvel or myth of the Magi? Holistic Nursing Practice 21(6):308-323. — PubMed PMID: 17978635

PubMed Topic Searches

  1. PubMed: myrrh capsule and schistosomiasis
  2. PubMed: myrrh capsule and fascioliasis
  3. PubMed: Myrrh and MRSA
  4. PubMed: Biofilm inhibition
  5. PubMed: H. pylori activity
  6. PubMed: Traditional anthelmintic use

Back to Table of Contents

Connections

Back to Table of Contents